Nasus Pharma Ltd. NSRX
3.29 USD +0.09 (+2.81%)
Nov 4, 2026, 9:44 AM EST
3.20 Day range 3.30
1.98 52-week range 9.50
- YTD
- -64.04%
- 1 year
- -58.88%
Financial health
Altman Z-Score
6.87 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -12.7×
FY 2022 5y median -46.0× FY 2025
P/S 0.0×
FY 2022 5y median 0.0× FY 2025
P/B 26.5×
FY 2022 5y median -21.5× FY 2025
P/FCF -14.9×
FY 2022 5y median -67.2× FY 2025
EV/EBITDA -14.7×
FY 2022 5y median -42.9× FY 2025
EV/Sales 0.0×
FY 2022 5y median 0.0× FY 2025
FCF Yield -6.7%
FY 2022 5y median -1.5% FY 2025
Profitability
Gross Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2022 5y median 0.0% FY 2025
ROE -211.6%
FY 2022 5y median 37.7% FY 2025
ROIC -169.9%
FY 2022 5y median 81.0% FY 2025
ROA -117.0%
FY 2022 5y median -225.2% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2022 FY 2025
Operating Income -354.9%
FY 2022 FY 2025
EPS (diluted) -323.5%
FY 2022 FY 2025
Free Cash Flow -641.7%
FY 2022 FY 2025
Financial Health
Current Ratio 2.2×
FY 2022 5y median 0.1× FY 2025
Quick Ratio 2.2×
FY 2022 5y median 0.1× FY 2025
Debt / Equity 0.0×
FY 2022 5y median -0.6× FY 2025
Net Debt / EBITDA 0.2×
FY 2022 5y median -0.8× FY 2025
Interest Coverage 0.0×
FY 2022 5y median -30.3× FY 2025
Dividends
Dividend Yield 0.0%
FY 2022 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2022 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31